Rennova Health, Inc. (RNVA) saw its value increase by 2.02% as the stock dropped $0 to finish the day at a closing price of $0.06. The stock was lighter in trading and has fluctuated between $0.05-$1.16 per share for the past year. The shares, which traded within a range of $0.06 to $0.06 during the day, are down by -57.55% in the past three months and down by -78.32% over the past six months. It is currently trading -20.15% below its 20 day moving average and -34.16% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $18.5 a share over the next twelve months. The current relative strength index (RSI) reading is 25.44.The technical indicator lead us to believe the stock will reverse recent losses any time soon.
Rennova Health, Inc. provides diagnostics and supportive software solutions to healthcare providers in the United States. It offers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management solutions, as well as intends to provide financial services in the form of loans to physician practices. The company provides toxicology, clinical pharmacogenetics, and esoteric testing services; develops Web-based system to place lab orders, track samples, and view test reports in real time; Web-enabled laboratory information management solutions; Medical Mime, which offers an electronic health record for substance abuse and behavioral health providers; and CollabRx that enhances cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients. Rennova Health, Inc. was founded in 2005 and is headquartered in West Palm Beach, Florida.
Mast Therapeutics, Inc. (MSTX) shares were down in last trading by -4.58% to $0.14. It experienced lighter than average volume on day. The stock decreased in value by almost -1.17% over the past week and fell -3.29% in the past month. It is currently trading 14.18% above its 50 day moving average and -47.73% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -80.93% decrease in value from its one year high of $0.7088. The RSI indicator value of 52.06, lead us to believe that it is a hold for now.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The companys lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
GNC Holdings, Inc. (GNC) traded within a range of $8.1 to $8.45 after opening the day at $8.43. The company has seen its stock decrease in value by -25.72% so far this year. The stock was down close to -2.26% on active volume in last trading session and closed at $8.2 per share. After the recent fall, the stock is currently holding -76.41% below its 52 week high of $35.9 and 7.47% above its 12-month low of $7.62. The shares are down by over -42.23% in the last three months, and the RSI indicator value of 30.94 is neither bullish nor bearish, tempting investors to stay on the sidelines.
GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products. The company operates through three segments: Retail, Franchise, and Manufacturing/Wholesale. Its products include vitamins, minerals, and herbal supplement products; and sports nutrition products, diet products, and other wellness products. The company sells its products under the GNC proprietary brands, including Mega Men, Ultra Mega, Total Lean, Pro Performance, Pro Performance AMP, Beyond Raw, GNC Puredge, GNC GenetixHD, and Herbal Plus, as well as under third-party brands. It operates a network of approximately 9,000 locations under the GNC brand worldwide. The company sells its products through company-owned retail stores; Websites, including GNC.com and LuckyVitamin.com, as well as Drugstore.com; domestic and international franchise activities; third-party contract manufacturing; and e-commerce and corporate partnerships. GNC Holdings, Inc. was founded in 1935 and is headquartered in Pittsburgh, Pennsylvania.